Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial
Lang I.,National Institute of Oncology |
Bell R.,Andrew Love Cancer Center |
Feng F.Y.,Cancer Institute and Hospital |
Lopez R.I.,National Oncology Institute |
And 5 more authors.
Clinical Oncology | Year: 2014
Aims: Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods: In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n=41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results: At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61%; 95% confidence interval: 48.7-80.4%), stable disease in 7/41 (17.1%) and progressive disease in 6/41 (14.6%). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95% confidence interval: 6-11 months) and the median overall survival was 25.0 months (16-33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32%) and diarrhoea (32%). Six patients (14.6%) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion: Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy. © 2013 The Royal College of Radiologists. Source
Bouchentouf S.M.,Hopital Militaire DInstruction Mohammed v |
Raissouni S.,National Oncology Institute |
Sall I.,Hopital Militaire DInstruction Mohammed v |
Kaoui H.E.,Hopital Militaire DInstruction Mohammed v |
And 5 more authors.
Oncology Reviews | Year: 2011
Gallbladder cancer (GBC) represents 3.8% of all gastrointestinal cancers and usually known to be of a poor prognosis. In 0.2-2.9% of cases, this cancer is found in cholecystectomy specimens. A better understanding of spread mode of this tumor helps a better surgical management. The aim of the present review is to underline the management of GBC based on the comprehension of risk factors and anatomic features. A Medline, PubMed database search was performed to identify articles published from 2000 to 2011 using the keywords 'carcinoma of gallbladder', 'incidental gallbladder cancer', 'gallbladder neoplasm' and 'cholecystectomy'. Some pathological situations such as chronic lithiasis and biliopancreatic junction abnormalities have been clearly identified as predisposing to GBC. Laparoscopy increases peritoneal and parietal tumor dissemination, thus, it should not be performed when GBC is suspected. Most determinant prognostic factors are nodal, perineural and venous involvement, invasion of the cystic duct and the tumor differentiation. The simple cholecystectomy is sufficient for tumors classified as T1a; for other cancers exceeding the muscularis, radical re-resection is required due to the high risk of recurrence. This aggressive surgery improved the overall survival of patients. There is still no standard adjuvant treatment; patients should be included in prospective trials. © 2011 Springer-Verlag. Source
Pavlik T.,Masaryk University |
Janousova E.,Masaryk University |
Mayer J.,Masaryk University |
Indrak K.,University Hospital Olomouc |
And 17 more authors.
American Journal of Hematology | Year: 2013
Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts≤10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks. © 2013 Wiley Periodicals, Inc. Source
Vrdoljak E.,University of Split |
Wojtukiewicz M.Z.,Medical University of Bialystok |
Pienkowski T.,Center of Oncology of Poland |
Bodoky G.,St.Laszlo Teaching Hospital |
And 4 more authors.
Croatian Medical Journal | Year: 2011
Aim To collect cancer epidemiology data in South Eastern European countries as a basis for potential comparison of their performance in cancer care. Methods The South Eastern European Research Oncology Group (SEEROG) collected and analyzed epidemiological data on incidence and mortality that reflect cancer management in 8 countries - Croatia, Czech Republic, Hungary, Romania, Poland, Slovakia, and Serbia and Montenegro in the last 20-40 years. Results The most common cancer type in men in all countries was lung cancer, followed by colorectal and prostate cancer, with the exception of the Czech Republic, where prostate cancer and colorectal cancer were more common. The most frequent cancer in women was breast cancer followed by colorectal cancer, with the exceptions of Romania and Central Serbia where cervical cancer was the second most common. Cancer mortality data from the last 20-40 years revealed two different patterns in men. In Romania and in Serbia and Montenegro, there was a trend toward an increase, while in the other countries mortality was declining, after increasing for a number of years. In women, a steady decline was observed over many years in the Czech Republic, Hungary, and Slovakia, while in the other countries it remained unchanged. Conclusions There are striking variations in the risk of different cancers by geographic area. Most of the international variation is due to exposure to known or suspected risk factors which provides a clear challenge to prevention. There are some differences in incidence and mortality that cannot be explained by exposure to known risk factors or treatment availabilities. Source
Lkhoyaali S.,National Oncology Institute |
Benhmida S.,National Oncology Institute |
Aitelhaj M.,National Oncology Institute |
Layachi M.,National Oncology Institute |
And 3 more authors.
Current Angiogenesis | Year: 2014
Thyroid cancers are characterized by a good prognosis but 10 to 15% of patients progress and become refractory to current therapies. Systemic treatment based on chemotherapy in these settings has shown limited efficacy, with response rates not exceeding 25%. At progression, differentiated thyroid cancer is characterized by a high level of expression of vascular endothelial growth factor (VEGF). This high expression of VEGF is associated with an aggressive tumor behavior and a poor clinical outcome. We will review the recent advances in targeting angiogenesis in the treatment of recurrent and metastatic thyroid carcinoma. © 2014 Bentham Science Publishers. Source